Leo Pharma files for marketing approval of tralokinumab in Japan

Pharmaceutical company Leo Pharma has announced it has filed a marketing authorization application with the Japanese health authority for the moderate-to-severe atopic eczema drug, tralokinumab.

Photo: Leo Pharma / PR

Leo Pharma has filed an application for marketing authorization of tralokinumab, the company’s treatment for patients with moderate-to-severe atopic eczema, in Japan, the company announces in a press release.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs